Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.

Bogden AE, Moreau JP, Gamba-Vitalo C, Deschamps de Paillette E, Tubiana M, Frindel E, Carde P.

Int J Cancer. 1998 Mar 30;76(1):38-46.

3.
4.

Systematic development of bombesin/gastrin-releasing peptide antagonists.

Coy DH, Jensen RT, Jiang NY, Lin JT, Bogden AE, Moreau JP.

J Natl Cancer Inst Monogr. 1992;(13):133-9. Review.

PMID:
1389686
5.

Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.

Bogden AE, Carde P, de Paillette ED, Moreau JP, Tubiana M, Frindel E.

Ann N Y Acad Sci. 1991;628:126-39. No abstract available.

PMID:
1648882
6.

Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline).

Bogden AE, Taylor JE, Moreau JP, Coy DH, LePage DJ.

Cancer Res. 1990 Jul 15;50(14):4360-5.

7.
8.

In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue.

Taylor JE, Bogden AE, Moreau JP, Coy DH.

Biochem Biophys Res Commun. 1988 May 31;153(1):81-6.

PMID:
2897854
9.

The 6-day subrenal capsule assay (SRCA): its criticism, biology and review of assay/clinical correlations.

Bogden AE, Cobb WR, LePage DJ.

Prog Clin Biol Res. 1988;276:139-204. Review. No abstract available.

PMID:
3051020
10.

The subrenal capsule assay (SRCA).

Bogden AE, Cobb WR.

Eur J Cancer Clin Oncol. 1986 Sep;22(9):1033-6. No abstract available.

PMID:
3780809
11.

Subrenal capsule assay: feasibility of transporting tissues to a central facility for testing.

Slagel DE, DeSimone P, Dillon M, LePage DJ, Bogden AE.

Cancer Treat Rep. 1985 Jun;69(6):717-8. No abstract available.

PMID:
4016776
12.

The subrenal capsule assay (SRCA) and its predictive value in oncology.

Bogden AE.

Ann Chir Gynaecol Suppl. 1985;199:12-27. Review.

PMID:
3904584
13.

Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance.

Donahoe PK, Krane I, Bogdén AE, Kamagata S, Budzik GP.

J Pediatr Surg. 1984 Dec;19(6):863-9.

PMID:
6084056
14.

9-Deazaadenosine--a new potent antitumor agent.

Chu MY, Zuckerman LB, Sato S, Crabtree GW, Bogden AE, Lim MI, Klein RS.

Biochem Pharmacol. 1984 Apr 15;33(8):1229-34.

PMID:
6712733
15.

Comparison of the human tumor cloning and subrenal capsule assays.

Bogden AE, Von Hoff DD.

Cancer Res. 1984 Mar;44(3):1087-90.

16.

Predictive testing with the subrenal capsule assay.

Bogden AE, Griffin W, Reich SD, Costanza ME, Cobb WR.

Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24.

PMID:
6428738
17.

Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy.

Griffin TW, Bogden AE, Reich SD, Antonelli D, Hunter RE, Ward A, Yu DT, Greene HL, Costanza ME.

Cancer. 1983 Dec 15;52(12):2185-92.

PMID:
6357424
18.

Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay.

Cobb WR, Bogden AE, Reich SD, Griffin TW, Kelton DE, LePage DJ.

Cancer Treat Rep. 1983 Feb;67(2):173-8. No abstract available.

PMID:
6825125
19.

Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: an update.

Bogden AE, Costanza ME, Reich SD, Griffin TW, Cobb WR.

Breast Cancer Res Treat. 1983;3(1):33-8.

PMID:
6871480
20.
21.

Nontuberculous mycobacterial infection attributable to Mycobacterium intracellulare serotype 10 in two rhesus monkeys.

Fleischman RW, du Moulin GC, Esber HJ, Ilievski V, Bogden AE.

J Am Vet Med Assoc. 1982 Dec 1;181(11):1358-62.

PMID:
7174460
22.

Responsiveness of gynecologic tumors to chemotherapeutic agents in the 6-day subrenal capsule assay.

Hunter RE, Reich SD, Griffin TW, Bogden AE.

Gynecol Oncol. 1982 Dec;14(3):298-306. No abstract available.

PMID:
7152362
23.

3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound.

Kranzfelder G, Hartmann RW, von Angerer E, Schönenberger H, Bogden AE.

J Cancer Res Clin Oncol. 1982;103(2):165-80.

PMID:
6284766
24.

Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay.

Bogden AE, Cobb WR, Lepage DJ, Haskell PM, Gulkin TA, Ward A, Kelton DE, Esber HJ.

Cancer. 1981 Jul 1;48(1):10-20.

PMID:
6263448
25.

Specific and nonspecific immune resistance enhancing activity of staphage lysate.

Esber HJ, DeCourcy SJ Jr, Bogden AE.

J Immunopharmacol. 1981;3(1):79-92.

PMID:
7019349
26.

18F-5-fluorouracil studies in humans and animals.

Lieberman LM, Wessels BW, Wiley AL Jr, Gatley SJ, Nickles RJ Jr, Young D, Wolberg WH, Bogden AE.

Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):505-9. No abstract available.

PMID:
7390932
27.

Characterization of animal tumors: summary.

Bogden AE.

Prog Clin Biol Res. 1980;37:303-10. No abstract available.

PMID:
7384089
28.

Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125.

Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, Neil GL.

Cancer Treat Rep. 1979 Mar;63(3):473-6.

PMID:
427827
29.

MER-BCG (NSC-143769): immunogenicity and toxicity of single and repeated intradermal injections in dogs.

Gray JH, Esber HJ, Fleischman RW, Schaeppi UH, McCracken D, Bogden AE.

J Immunopharmacol. 1979;1(3):377-98.

PMID:
553113
30.

Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice.

Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esber HJ.

Exp Cell Biol. 1979;47(4):281-93.

PMID:
467773
31.

Predictive experimental animal tumor models: a concept.

Bogden AE, Esber HJ.

Natl Cancer Inst Monogr. 1978 Dec;(49):263-7.

PMID:
758024
32.
33.

The concept of induction and elicitation as an immunotherapeutic approach.

Bogden AE, Esber HJ.

Natl Cancer Inst Monogr. 1978 Dec;(49):365-7.

PMID:
748794
34.

Effect of serial passage in nude athymic mice on the growth characteristics and chemotherapy responsiveness of 13762 and R3230AC mammary tumor xenografts.

Bogden AE, Kelton DE, Cobb WR, Gulkin TA, Johnson RK.

Cancer Res. 1978 Jan;38(1):59-64. No abstract available.

35.

Induction of murine erythroleukemia cells to differentiate: a model for the detection of new anti-tumor drugs.

Marks PA, Reuben R, Epner E, Breslow R, Cobb W, Bogden AE, Rifkind RA.

Antibiot Chemother (1971). 1978;23:33-41. No abstract available.

PMID:
274100
36.

Predicting the course of Gompertzian growth.

Norton L, Simon R, Brereton HD, Bogden AE.

Nature. 1976 Dec 9;264(5586):542-5. No abstract available.

PMID:
1004590
37.

Circadian pattern of prolactin and growth hormone levels in female rats of two strains.

Esber HJ, Kuo E, Bogden AE.

Lab Anim Sci. 1976 Apr;26(2 Pt l):186-9.

PMID:
944833
39.

Population frequency of erythrocyte antigens in the rhesus monkey.

Bogden AE, Gray JH, Brule M.

Lab Anim Sci. 1974 Dec;24(6):910-3. No abstract available.

PMID:
4374595
40.

The effect of perphenazine-induced serum prolactin response on estrogen-primed mammary tumor-host systems, 13762 and R-35 mammary adenocarcinomas.

Bogden AE, Taylor DJ, Kuo EY, Mason MM, Speropoulos A.

Cancer Res. 1974 Nov;34(11):3018-25. No abstract available.

41.
42.

Oncogenicity of the R-35 rat mammary tumor virus.

Bogden AE, Cobb WR, Ahmed M, Alex S, Mason MM.

J Natl Cancer Inst. 1974 Oct;53(4):1073-7. No abstract available.

PMID:
4372364
43.

Variation in serum hormone concentrations in different rat strains.

Esber HJ, Menninger FF Jr, Bogden AE.

Proc Soc Exp Biol Med. 1974 Sep;146(4):1050-3. No abstract available.

PMID:
4418008
44.

Toxicity of neocarzinostatin (NSC-69856): an antitumor antibiotic with radiomimetic and antigenic characteristics.

Schaeppi U, Menninger F, Fleischman RW, Bogden AE, Schein PS, Cooney DA.

Cancer Chemother Rep 3. 1974 Sep;5(1):43-52. No abstract available.

PMID:
4213508
45.
46.

Biochemical characterization of a cancer immunotherapeutic agent: MSF-MB.

Esber HJ, Hagopian M, Bogden AE.

J Natl Cancer Inst. 1974 Jul;53(1):209-12. No abstract available.

PMID:
4835106
47.

Immunological deficiency associated with cigarette smoke inhalation by mice. Primary and secondary hemagglutinin response.

Esber HJ, Menninger FF Jr, Bogden AE, Mason MM.

Arch Environ Health. 1973 Aug;27(2):99-104. No abstract available.

PMID:
4721205
48.

Immunoadjuvant activity of bacterial fractions on antibody-forming cells during the primary immune response period.

Esber HJ, Valentine EA, Taylor DJ, Bogden AE.

Immunol Commun. 1973;2(6):585-95. No abstract available.

PMID:
4359287
49.

History of a rhesus monkey adenocarcinoma containing virus particles resembling oncogenic RNA viruses.

Mason MM, Bogden AE, Ilievski V, Esber HJ, Baker JR, Chopra HC.

J Natl Cancer Inst. 1972 May;48(5):1323-31. No abstract available.

PMID:
4624149
50.

Nonspecific stimulation of tumor-associated immunity by methanol-soluble fraction of Mycobacterium butyricum.

Esber HJ, Menninger FF Jr, Taylor DJ, Bogden AE.

Cancer Res. 1972 Apr;32(4):795-803. No abstract available.

Supplemental Content

Loading ...
Support Center